Gland Pharma Ltd, the Hyderabad-based company is one of the fastest-growing generic injectable companies. It manufactures a diversified range of high-quality complex injectables. The company offers products like sterile injectables, oncology, and ophthalmics, complex injectables (peptides, suspensions, hormonal products, long-acting injectables), NCE-1s, First-to-File products, etc.
The company follows a B2B model to sell its products in more than 60 countries including the US, Canada, Australia, India, Europe, etc. Leading pharma companies i.e. Sagent Pharmaceuticals, Apotex Inc. Athnex Pharmaceutical Division, LLC, Fresenius Kabi USA, LLC, etc. are some of the key customers.
It has 7 robust manufacturing units in India comprising 4 finished formulations facilities, 22 production lines, and 3 APIs.
Company Strengths
The extensive product portfolio of complex injectables.
Diversified B2B model with a targeted B2C model in India.
Strong manufacturing capabilities.
Robust financial track record.
Experienced and qualified managerial team.
Gland Pharma IPO Details
Issue Type | Book Built Issue IPO |
Face Value | ₹1 per equity share |
IPO Price | ₹1490 to ₹1500 per equity share |
Market Lot | 10 Shares |
Min Order Quantity | 10 Shares |
Listing At | BSE, NSE |
BSE Script Code | 543245 |
NSE Symbol | GLAND |
ISIN | INE068V01023 |
Issue Size | Aggregating up to ₹6,479.55 Cr |
Fresh Issue | Aggregating up to ₹1,250.00 Cr |
Offer for Sale | Aggregating up to ₹5,229.55 Cr |
Gland Pharma IPO Tentative Timetable
PARTICULAR | DATE |
IPO Open Date | 9-Nov-20 |
IPO Close Date | 11-Nov-20 |
Basis of Allotment Date | 17-Nov-20 |
IPO Listing Date | 20-Nov-20 |
Gland Pharma IPO Lot Size
Application | Lots | Shares | Amount (Cut-off) |
Minimum | 1 | 10 | ₹15,000 |
Maximum | 13 | 130 | ₹195,000 |
IPO Allotment Status
please click hare to check IPO Allotment Status For Gland Pharma Limited
Company Financials:
PARTICULAR | 30-Jun-20 | 31-Mar-20 | 31-Mar-19 | 31-Mar-18 |
Total Assets | 46,912.65 | 40,860.39 | 35,235.49 | 29,294.68 |
Total Revenue | 9,162.89 | 27,724.08 | 21,297.67 | 16,716.82 |
Profit After Tax | 3,135.90 | 7,728.58 | 4,518.56 | 3,210.51 |
Company Promoters:
Fosun Pharma Industrial Pte. Ltd and Shanghai Fosun Pharmaceutical (Group) Co. Ltd is the company promoters.
Objects of the Issue:
The net proceeds from the IPO will be used for the following purposes:
- To finance the incremental working capital requirements of our Company
- To meet funding requirements for capital expenditure requirements
- To meet the general corporate purposes
Registrar & Company Details
Company Contact Information | Gland Pharma IPO Registrar |
Gland Pharma Limited Sy. No. 143 – 148, 150 and 151, Near Gandi Maisamma ‘X’ Roads, D.P. Pally,Dundigal Medchal-Malkajgiri District, Hyderabad Phone: +91 40 3051 0999 Email: investors@glandpharma.com Website: http://www.glandpharma.com | Link Intime India Private Ltd Link Intime India Private Ltd C 101, 247 Park, L.B.S.Marg, Vikhroli (West), Mumbai – 400083 Phone: +91-22-4918 6270 Email: glandpharma.ipo@linkintime.co.in Website: http://www.linkintime.co.in |